Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Amicus Therapeutics, Inc. FOLD
$11.37
-$0.31 (-2.70%)
На 18:00, 12 мая 2023
+23.13%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3385296400.00000000
-
week52high
13.84
-
week52low
7.13
-
Revenue
329233000
-
P/E TTM
-15
-
Beta
0.80865000
-
EPS
-0.85000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 24 февр 2022 г. |
| SVB Leerink | Outperform | Market Perform | 14 янв 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 13 янв 2022 г. |
| Stifel | Buy | Hold | 15 ноя 2021 г. |
| SVB Leerink | Market Perform | Market Perform | 30 сент 2021 г. |
| Morgan Stanley | Equal-Weight | 09 сент 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 08 ноя 2022 г. |
| BTIG | Buy | Buy | 18 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Crowley John F | D | 0 | 56596 | 01 февр 2023 г. |
| Crowley John F | D | 1004669 | 147316 | 01 февр 2023 г. |
| Crowley John F | A | 1151985 | 56596 | 01 февр 2023 г. |
| Crowley John F | A | 1095389 | 83333 | 01 февр 2023 г. |
| Campbell Bradley L | D | 42225 | 11700 | 01 февр 2023 г. |
| Campbell Bradley L | D | 845129 | 20000 | 01 февр 2023 г. |
| Campbell Bradley L | A | 865129 | 11700 | 01 февр 2023 г. |
| Rosenberg Ellen | D | 332345 | 31839 | 24 янв 2023 г. |
| Quimi Daphne | D | 398532 | 6923 | 18 янв 2023 г. |
| Clark David Michael | D | 241067 | 7382 | 18 янв 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7267160 | -36504 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 5485450 | 157168 | 31 авг 2020 г. |
| SPDR S&P Biotech ETF | 5075500 | -261122 | 31 авг 2020 г. |
| db x-trackers S&P 500 UCITS ETF | 4898210 | 0 | 31 авг 2020 г. |
| Vanguard Small-Cap Index Fund | 6402730 | -51583 | 31 июл 2020 г. |
| Vanguard Small-Cap Growth Index Fund | 3889440 | -24981 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 3677250 | -27286 | 31 июл 2020 г. |
| Fidelity Select Biotechnology Portfolio | 3282080 | -832400 | 31 июл 2020 г. |
| JPMorgan Small Cap Growth Fund | 3247160 | 73725 | 31 июл 2020 г. |
| Janus Henderson Triton Fund | 4008700 | -181994 | 31 мар 2020 г. |
Новостная лента
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow
Zacks Investment Research
11 мая 2023 г. в 09:10
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
10 мая 2023 г. в 09:56
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.30 per share a year ago.
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
GlobeNewsWire
01 мая 2023 г. в 07:00
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2023.
These Are the Top 10 Holdings of Avoro Capital Advisors
24/7 Wall Street
17 апр 2023 г. в 22:54
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
Barrons
14 апр 2023 г. в 14:45
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.